合富中国：预计2025年全年归属净利润亏损2500万元至3600万元

Core Viewpoint - Company expects a net profit loss of 25 million to 36 million yuan for the full year of 2025 due to various challenges in the market and operational adjustments [1] Group 1: Performance Forecast - Company anticipates a net profit loss of 25 million to 36 million yuan for 2025 [1] - The forecasted loss is attributed to changes in the macro environment and the impact of centralized procurement policies in the in-vitro diagnostics industry [2] Group 2: Reasons for Performance Changes - The competitive landscape is being reshaped, leading to a decrease in product procurement prices and fluctuations in order volumes, which pose challenges to sales revenue and gross margin [2] - Despite cost-saving measures, fixed expenditures remain constant, and investments in talent optimization and capability upgrades have contributed to the expected losses [2] - The company is adjusting its business layout and strategy, focusing on the "ACME" proprietary products, increasing R&D investment, and expanding the market development team to enhance high-value services for hospital clients [2] Group 3: Financial Performance - For the first three quarters of 2025, the company's main revenue was 549 million yuan, a year-on-year decrease of 22.8% [3] - The net profit attributable to shareholders was -12.39 million yuan, a decline of 146.65% year-on-year [3] - The gross margin was reported at 15.84%, with a debt ratio of 27.18% [3]